*ST西發(000752.SZ):控股股東擬投資年產30萬噸啤酒擴產建設項目
格隆匯10月19日丨*ST西發(000752.SZ)公佈,公司控股股東西藏盛邦控股有限公司與拉薩經濟技術開發區管理委員會於 2021年10月19日簽署了《項目投資協議》。
項目名稱:年產30萬噸啤酒擴產建設項目;項目投資內容:新建聯合釀造車間,包括原料暫存倉、糖化工段、發酵工段、發酵罐區、動力設施等,配套完善污水處理站。
項目投資規模:西藏盛邦控股有限公司在拉薩經濟技術開發區內設立獨立法人的項目公司,投資總額不低於10億元,實繳註冊資本不低於30000萬元(三年內完成實繳),註冊資本佔投資總額的比例符合國家有關要求。項目達產後,預計年產值約15億元,預計年納税約1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.